PURPOSE: To report the therapeutic response in the treatment of juxtafoveal choroidal neovascular membrane (CNVM) secondary to traumatic choroidal rupture with intravitreal bevacizumab. METHODS: A 20-year-old man presented with distortion of central vision following blunt trauma and was found to have juxtafoveal, classic CNVM associated with a choroidal rupture. The patient underwent intravitreal bevacizumab (1.25 mg/0.05 mL) and was periodically followed up. RESULTS: Four weeks post injection, best-corrected visual acuity improved to 20/20. Optical coherence tomography revealed regression of CNVM and resolution of subretinal fluid. The anatomic and functional status of the treated eye was maintained at 6 months follow-up. No treatment-related ocular or systemic adverse effects were noted. CONCLUSION: Bevacizumab appears to be safe and effective in the treatment of CNVM secondary to choroidal rupture.
PURPOSE: To report the therapeutic response in the treatment of juxtafoveal choroidal neovascular membrane (CNVM) secondary to traumatic choroidal rupture with intravitreal bevacizumab. METHODS: A 20-year-old man presented with distortion of central vision following blunt trauma and was found to have juxtafoveal, classic CNVM associated with a choroidal rupture. The patient underwent intravitreal bevacizumab (1.25 mg/0.05 mL) and was periodically followed up. RESULTS: Four weeks post injection, best-corrected visual acuity improved to 20/20. Optical coherence tomography revealed regression of CNVM and resolution of subretinal fluid. The anatomic and functional status of the treated eye was maintained at 6 months follow-up. No treatment-related ocular or systemic adverse effects were noted. CONCLUSION:Bevacizumab appears to be safe and effective in the treatment of CNVM secondary to choroidal rupture.